Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 5Unknown 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 7Rectal Neoplasms 5Nasopharyngeal Carcinoma 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms by Site 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × spartalizumab × Clear all
NCT06471205 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
52 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡